We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SLSN Soars 86% as It Posts Q3 Earnings on Manufacturing Efficiency
Read MoreHide Full Article
Shares of Solesence, Inc. (SLSN - Free Report) have surged 85.5% since the company reported its earnings for the quarter ended Sept. 30, 2026. This compares to the S&P 500 Index’s 2.7% decline over the same period. Over the past month, the stock has gained 89.3%, outperforming the S&P 500’s 4.2% drop.
Solesence reported earnings of 5 cents per share for the third quarter of 2026 against a loss of 1 cent in the year-ago quarter.
Net revenues increased 38.1% year over year to $20.2 million from $14.6 million, supported by stronger demand from brand partners, improved manufacturing efficiency and a favorable product mix.
Net income reached a company-record $3.7 million compared to a net loss of $1 million in the prior-year quarter.
Gross profit more than doubled to $7.9 million from $3.5 million in the prior-year quarter. Gross margin expanded 1,550 basis points to 39.3% from 23.8%, reflecting operational improvements and a favorable product mix.
Selling, general and administrative expenses fell 8.4% year over year to $2.8 million, while research and development expenses remained stable at $1.1 million.
Operating income reached $4 million, reversing an operating loss of $0.7 million a year earlier. Adjusted EBITDA improved to $4.3 million from a loss of $0.3 million in the prior-year quarter.
Interest expenses declined 23.9% to $0.26 million from $0.34 million.
As of Sept. 30, 2026, cash totaled $1.27 million compared with $1.29 million as of Dec. 31, 2025. Total assets dropped to $44.4 million from $46.4 million, while stockholders' equity increased to $16.8 million from $14 million.
SLSN's Management Commentary
Chief executive officer Kevin Cureton highlighted the completion of the primary investment and implementation phase of the company's operational excellence initiative under its Transform and Transcend strategy.
Management emphasized that expanded production capacity and improved efficiency have strengthened Solésence's ability to meet customer demand while supporting profitable growth.
Chief financial officer Laura Riffner noted that record revenues, profitability and substantial margin expansion provide a stronger foundation for 2027.
Management also highlighted its expanding relationships with more than 60 brand partners and a portfolio exceeding 300 stock-keeping units.
Factors Influencing SLSN's Performance
Operational improvements were central to the quarterly turnaround. Overall equipment effectiveness increased to 55% at the end of the quarter from 40% at the end of the prior-year quarter, strengthening manufacturing execution.
Direct labor costs declined by more than $2 million on a year-to-date basis compared with 2025. Lower indirect costs and improved production yields supported profitability.
Product innovation remains another growth driver. Management highlighted opportunities arising from the FDA's approval of bemotrizinol, a new sunscreen ingredient, and its potential integration into Solésence's proprietary formulations.
However, management acknowledged that additional improvements in labor efficiency and production yields remain necessary to sustain margin growth.
SLSN's 2026 Outlook
Management reiterated its expectation of achieving at least $65 million in shipped and on-hand orders by year-end 2026, representing a third consecutive year of record revenues.
The company maintained its full-year gross margin floor of 30%, supported by continued manufacturing improvements.
Solesence continues to anticipate double-digit adjusted EBITDA growth for 2026, although management indicated that growth could fall slightly below its previously communicated target.
The company expects further operational improvements, product innovation and international expansion to support growth in 2027, with management targeting adjusted EBITDA margins above 20% over the longer term.
Image: Bigstock
SLSN Soars 86% as It Posts Q3 Earnings on Manufacturing Efficiency
Shares of Solesence, Inc. (SLSN - Free Report) have surged 85.5% since the company reported its earnings for the quarter ended Sept. 30, 2026. This compares to the S&P 500 Index’s 2.7% decline over the same period. Over the past month, the stock has gained 89.3%, outperforming the S&P 500’s 4.2% drop.
Solesence reported earnings of 5 cents per share for the third quarter of 2026 against a loss of 1 cent in the year-ago quarter.
Net revenues increased 38.1% year over year to $20.2 million from $14.6 million, supported by stronger demand from brand partners, improved manufacturing efficiency and a favorable product mix.
Net income reached a company-record $3.7 million compared to a net loss of $1 million in the prior-year quarter.
Solesence, Inc. Price, Consensus and EPS Surprise
Solesence, Inc. price-consensus-eps-surprise-chart | Solesence, Inc. Quote
SLSN's Other Key Financial Metrics
Gross profit more than doubled to $7.9 million from $3.5 million in the prior-year quarter. Gross margin expanded 1,550 basis points to 39.3% from 23.8%, reflecting operational improvements and a favorable product mix.
Selling, general and administrative expenses fell 8.4% year over year to $2.8 million, while research and development expenses remained stable at $1.1 million.
Operating income reached $4 million, reversing an operating loss of $0.7 million a year earlier. Adjusted EBITDA improved to $4.3 million from a loss of $0.3 million in the prior-year quarter.
Interest expenses declined 23.9% to $0.26 million from $0.34 million.
As of Sept. 30, 2026, cash totaled $1.27 million compared with $1.29 million as of Dec. 31, 2025. Total assets dropped to $44.4 million from $46.4 million, while stockholders' equity increased to $16.8 million from $14 million.
SLSN's Management Commentary
Chief executive officer Kevin Cureton highlighted the completion of the primary investment and implementation phase of the company's operational excellence initiative under its Transform and Transcend strategy.
Management emphasized that expanded production capacity and improved efficiency have strengthened Solésence's ability to meet customer demand while supporting profitable growth.
Chief financial officer Laura Riffner noted that record revenues, profitability and substantial margin expansion provide a stronger foundation for 2027.
Management also highlighted its expanding relationships with more than 60 brand partners and a portfolio exceeding 300 stock-keeping units.
Factors Influencing SLSN's Performance
Operational improvements were central to the quarterly turnaround. Overall equipment effectiveness increased to 55% at the end of the quarter from 40% at the end of the prior-year quarter, strengthening manufacturing execution.
Direct labor costs declined by more than $2 million on a year-to-date basis compared with 2025. Lower indirect costs and improved production yields supported profitability.
Product innovation remains another growth driver. Management highlighted opportunities arising from the FDA's approval of bemotrizinol, a new sunscreen ingredient, and its potential integration into Solésence's proprietary formulations.
However, management acknowledged that additional improvements in labor efficiency and production yields remain necessary to sustain margin growth.
SLSN's 2026 Outlook
Management reiterated its expectation of achieving at least $65 million in shipped and on-hand orders by year-end 2026, representing a third consecutive year of record revenues.
The company maintained its full-year gross margin floor of 30%, supported by continued manufacturing improvements.
Solesence continues to anticipate double-digit adjusted EBITDA growth for 2026, although management indicated that growth could fall slightly below its previously communicated target.
The company expects further operational improvements, product innovation and international expansion to support growth in 2027, with management targeting adjusted EBITDA margins above 20% over the longer term.